NSC 14613

CAS No. 91396-88-2

NSC 14613( NSC 14613 | N’-phenyl-hydrazine-Isonicotinic acid )

Catalog No. M16567 CAS No. 91396-88-2

PluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 28 In Stock
10MG 47 In Stock
25MG 76 In Stock
50MG 110 In Stock
100MG 160 In Stock
200MG 228 In Stock
500MG 383 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    NSC 14613
  • Note
    Research use only, not for human use.
  • Brief Description
    PluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.
  • Description
    PluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.
  • In Vitro
    PluriSIn 1, a small-molecule inhibitor of stearoyl-coA desaturase (SCD), on induced pluripotent stem cells (iPS)-derived cardiomyocytes (CM). PluriSIn 1 treatment significantly decreases the mRNA and protein level of Nanog, a marker for both cell pluripotency and tumor progression; importantly, we provide evidence that PluriSIn 1 treatment at 20 μM for 1 day significantly induces the apoptosis of Nanog-positive iPS derivates (iPSD). In addition, PluriSIn 1 treatment at 20 μM for 4 days diminished Nanog-positive stem cells in cultured iPSD while not increasing apoptosis of iPS-derived CM. To investigate whether PluriSIn 1 treatment prevents tumorigenicity of iPSD after cell transplantation, we intramyocardially injected PluriSIn 1- or DMSO-treated iPSD in a mouse model of myocardial infarction (MI). DMSO-treated iPSD readily formed Nanog-expressing tumors 2 weeks after injection, which is prevented by treatment with PluriSIn 1. Moreover, treatment with PluriSIn 1 does not change the expression of cTnI, α-MHC, or MLC-2v, markers of cardiac differentiation (P>0.05, n=4). Importantly, PluriSIn 1-treated iPS-derived CM exhibits the ability to engraft and survive in the infarcted myocardium.
  • In Vivo
    ——
  • Synonyms
    NSC 14613 | N’-phenyl-hydrazine-Isonicotinic acid
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    SCD
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    91396-88-2
  • Formula Weight
    213.24
  • Molecular Formula
    C12H11N3O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 43 mg/mL (201.65 mM)
  • SMILES
    O=C(NNC1=CC=CC=C1)C2=CC=NC=C2
  • Chemical Name
    N'-phenylisonicotinohydrazide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ben-David U, et al. Cell Stem Cell, 2013, 12(2), 167-179.
molnova catalog
related products
  • JC2-11

    JC2-11 is an inhibitory compound for inflammation.JC2-11 inhibits the recruitment domain-containing proteins NLRC 4, atypical in melanoma 2 (AIM 2) and atypical (NC) inflammatory vesicles by disrupting reactive oxygen species (ROS) production and caspase-1 activity.

  • LDH-IN-1

    LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC50s of 32 and 27 nM for LDHA and LDHB, respectively.?LDH-IN-1 inhibits the growth of MiaPaCa2 pancreatic cancer and A673 sarcoma cells with IC50s of 2.23 and 1.21 μM).

  • SW209049

    SW209049 is a stearoyl-CoA 9-desaturase inhibitor. SW209049 exhivits potent activity against H2122 cell with IC50 of 0.13uM.